 VolitionRx NYSE-A:VNRX Limited rounded out a strong first quarter by receiving a 10 million milestone payment from Heska Corporation for the companys Nu.Q Vet Cancer Screening Test. In exchange for granting Heska exclusive worldwide rights to sell the Nu.Q Vet Cancer Screening Test for companion animals, Volition has received a 10 million upfront payment and is eligible to receive up to a further 18 million based upon the achievement of near and mid-term milestones. 